May 07, 2025 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced data from VLTR-559, its long-acting anti-VEGF biologic in ...

A total of 150 participants will be enrolled and randomized in a 1:1:1 ratio to the IBI302 4 mg group, the IBI302 8 mg group, and the Faricimab (anti-VEGF/ANG-2 bispecific antibody) 6 mg group.

They attached magnetically responsive nanoridges, or MANs, to these grooves using flexible polymer linkers and coated them with RGD, a short peptide that facilitates cell adhesion through integrin ...

but was not affected by addition of ß1 integrin antibody (Fig. 6d). By contrast, a neutralizing antibody specific for VEGF receptor 2 (VEGFR2) did not affect lactadherin-induced AKT ...

Are the new-generation anti-VEGF agents more specifically beneficial for pigment epithelial detachment (PED)? Two specialists at the Congress on Controversies in Ophthalmology shared their views.

One key player in this process is integrin, a protein found on the surface of cells that facilitates adhesion, helping them stick to other surfaces. In this scenario, integrin is what the white ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

BioNTech on Tuesday revealed Phase Ib/II data for its investigational PD-L1/VEGF bispecific antibody BNT327, touting encouraging response and survival outcomes in patients with locally advanced or ...

Tumors secrete specific growth factors, such as the vascular endothelial growth factor (VEGF), to stimulate angiogenesis, ensuring a steady blood supply that helps and supports rapid growth and ...

In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development ...

1 OTT166 is a novel, selective RGD integrin inhibitor with anti-VEGF and other growth factor modulating effects with the potential to modulate multiple drivers of DR developed as an eye drop to ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The ...